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Background: In the absence of thromboprophylaxis, patients undergoing total hip arthroplasty (THA) are at
increased risk for venous thromboembolism (VTE). The objective of this study was to compare the efficacy and
safety of edoxaban with enoxaparin for the prevention of VTE after THA in Japan.
Methods: This was a phase 3, double-blind, double-dummy, noninferiority study. Patients undergoing elective,
unilateral primary THA were randomized to receive edoxaban 30 mg once daily (n = 307) or enoxaparin 2000 IU
(equivalent to 20 mg) twice daily (n = 303) for 11 to 14 days. The primary efficacy endpoint was the incidence of
VTE. Safety endpoints included the incidence of major or clinically relevant nonmajor (CRNM) bleeding.
Results: The incidence of VTE, based on venography and clinical surveillance, was 2.4 % in the edoxaban group
and 6.9 % in the enoxaparin group (P <0.001). The absolute difference in the incidence of VTE was −4.5 % (95 %
confidence interval [CI]: −8.6, −0.9), which was within the noninferiority margin set at 8 % for the difference and
established the noninferiority of edoxaban to enoxaparin. Since the upper limit of the 95 % CI of the absolute
difference was less than 0 %, the superiority of edoxaban over enoxaparin was demonstrated. The incidence of
major or CRNM bleeding was 2.6 % in the edoxaban group and 3.7 % in the enoxaparin group (P = 0.475).
Conclusions: Oral edoxaban 30 mg once daily was superior to subcutaneous enoxaparin 2000 IU twice daily in
the prevention of VTE following THA without increasing the risk for major or CRNM bleeding.
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Venous thromboembolism (VTE), comprising deep vein
thrombosis (DVT) and pulmonary embolism (PE), is a
leading cause of morbidity and mortality [1]. In the
absence of thromboprophylaxis, 40 % to 60 % of patients
undergoing total hip arthroplasty (THA) or total knee
arthroplasty (TKA) will develop venographic evidence of
DVT, and approximately 1 in 300 THA patients will experi-
ence a fatal PE [2]. The morbidity and mortality associated* Correspondence: fuji-th@umin.ac.jp
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THA patients [3, 4].
In Japan, the standard of care for thromboprophylaxis
following THA is the low-molecular weight heparin
(LMWH) enoxaparin 2000 IU twice daily, initiated 24 to
36 h after surgery and continued for 14 days [4–6].
Fondaparinux, a selective factor Xa inhibitor administered
by subcutaneous injection, is another potent anticoagulant
approved for the prevention of VTE in Japanese patients
undergoing THA or TKA [7].
Edoxaban, a direct, once-daily factor Xa inhibitor [8],
is a new oral anticoagulant that has been studied for the
prevention of VTE [9, 10]. In phase 2 studies of patients
undergoing elective THA [10] or TKA [9], edoxabane distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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compared with dalteparin and placebo, respectively.
Another phase 2 study in patients following THA demon-
strated no significant difference in the incidence of VTE
for patients who received edoxaban compared with enoxa-
parin [11]. There was a low incidence of major or clinic-
ally relevant nonmajor (CRNM) bleeding observed with
edoxaban in these studies. Results from the phase 2 stud-
ies in patients following THA led to the initiation of the
phase 3 Studying Thrombosis After Replacement Surgery
J-V (STARS J-V) trial. The objective of the STARS J-V trial
was to compare the efficacy and safety of edoxaban 30 mg
once daily with enoxaparin 2000 IU (equivalent to 20 mg)
twice daily in Japanese patients for the prevention of VTE
following elective, unilateral, primary THA.
Materials and methods
Study design
This was a randomized, double-blind, double-dummy,
parallel-group, enoxaparin-controlled, multicenter phase 3
trial (ClinicalTrials.gov Identifier: NCT01181167) of edox-
aban in patients undergoing unilateral THA (excluding re-
vision THA). The study protocol, information for patients,
and informed consent forms were reviewed and approved
by an institutional review board, and the study was con-
ducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines.
Patients were randomized 1:1 to receive oral edoxaban
30 mg once daily or subcutaneous enoxaparin 2000 IU
twice daily for 11 to 14 days. Treatment with edoxaban
(or edoxaban placebo) was administered within 6 to 24 h
after surgery and once daily each morning thereafter;
enoxaparin injection (or enoxaparin placebo injection)
was administered 24 to 36 h after surgery and twice daily
from the following day onward (Fig. 1). The enoxaparin
dosing regimen was set according to the approved regi-
men for enoxaparin sodium in Japan. Patients were per-
mitted to use mechanical physiotherapy, which included
elastic stockings or intermittent pneumatic compression
of the sole of the foot or of the lower legs and thigh. Ven-
ography of the lower limbs was performed within 24 hFig. 1 Study design. BID, twice a day; IU, international unit; QD, once dailyafter either the end of treatment or after the last dose of
study drug when treatment was discontinued, or within
96 h for reasons such as difficulty in establishing an intra-
venous line. Investigations, observations, examinations,
and urine and blood sample collection (for urinalysis,
edoxaban plasma concentration measurements, assess-
ment of pharmacodynamic [PD] indices, and hematology
tests) were performed at presurgical evaluation, pretreat-
ment (postsurgery), on day seven, and on the completion
day of treatment. Follow-up examination was performed
at 25 to 35 days after the last dose of study drug. The
occurrence of thromboembolic events, bleeding, and all
other adverse events (AEs) were recorded throughout the
study. If applicable, site, duration, and total time of
physiotherapy use were recorded.
Selection of study population
Patients 20 to 85 years of age undergoing unilateral THA
were included. Presurgical exclusion criteria included risk
for bleeding (eg, history of intracranial bleeding, comorbid
gastrointestinal bleeding or peptic ulcer within the previ-
ous 3 months, or prothrombin time [PT] prolongation
above the upper limit of the normal [ULN]); risk for
thromboembolism (eg, history of symptomatic DVT or
PE, coagulation disease at high risk for thromboembolism,
or history of lower limb fracture within the previous
6 months); previous TKA; expected joint replacement of
the other lower limb at the same time of anesthesia;
weight <40 kg; severe renal impairment (creatinine clear-
ance [CLCR] of <30 mL/min) [12]; evidence of hepatic
dysfunction (serum aspartate aminotransferase [AST] or
serum alanine aminotransferase [ALT] levels ≥2 times the
ULN or total bilirubin ≥1.5 times the ULN); previous
treatment with edoxaban; and current antithrombotic
therapy for another complication. Postsurgical exclusion
criteria included abnormal bleeding from the puncture
site during spinal anesthesia, need for repeat surgery
before the start of study treatment, abnormal or excessive
bleeding experienced during surgery, and inability to take
oral medication. All patients provided written informed
consent prior to initiation of any study-related procedures.
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tomatic DVT, PE, or major bleeding; had evidence of hep-
atic dysfunction; had persistent systolic blood pressure of
>180 mm Hg or diastolic blood pressure of >110 mm Hg;
required anticoagulant drugs, antiplatelet drugs, thrombo-
lytic drugs, or drugs that might affect thrombus forma-
tion; needed postsurgical epidural anesthesia; experienced
an AE that the investigator or subinvestigator judged was
sufficient for study discontinuation; voluntarily requested
to withdraw; were found to be ineligible for continued
participation in the study for any reason; or if the investi-
gator judged that the study should be discontinued for the
patient.Study endpoints
The primary efficacy endpoint was the incidence of VTE
from the start of treatment to venography at the end of
treatment, including asymptomatic DVT and symptomatic
PE or DVT. Secondary efficacy endpoints were the inci-
dence of symptomatic DVT, proximal DVT, symptomatic
PE, or VTE-related death; the incidence of asymptomatic
or symptomatic DVT; the incidence of symptomatic or
proximal DVT; the incidence of symptomatic PE; the inci-
dence of VTE-related deaths; and the incidence of all-
cause deaths.
Safety endpoints included the incidences of major
bleeding; CRNM bleeding; major or CRNM bleeding;
any bleeding (major, CRNM, and minor); and minor
bleeding events from the start of treatment to the day
after the end of treatment. Major bleeding was defined
as fatal bleeding; clinically overt bleeding accompanied
by a decrease in hemoglobin of >2 g/dL; clinically overt
bleeding requiring hemotransfusion with more than four
units of blood (1 unit = approximately 200 mL); retroperi-
toneal, intracranial, intraocular, or intrathecal bleeding; or
bleeding requiring repeat surgery. CRNM bleeding was
bleeding that was not characterized as major, but corre-
sponded to any of the following: hematoma ≥5 cm in long
diameter, epistaxis or gingival bleeding in the absence of
external factors and lasting ≥5 min, gastrointestinal bleed-
ing, gross hematuria persistent after 24 h of onset, or any
other bleeding deemed clinically significant by the investi-
gator. Minor bleeding was any bleeding event (including a
positive occult blood reaction) that was not considered a
major or CRNM event. Additional safety endpoints were
the incidences of AEs and adverse drug reactions (ADRs).
Thromboembolic events were assessed by the Thrombo-
embolic Event Assessment Committee, which made the
final assessment of thromboembolic events based on
blinded copies of the test results (radiographic films, etc.)
collected from each study site. Bleeding events were
assessed by the Bleeding Event Assessment Committee,
which was responsible for the final assessment of bleedingevents. Results of the assessments by these committees
were defined as the final evaluation.
Edoxaban plasma concentrations were measured by
liquid chromatography-tandem mass spectrometry; the
lower limit of quantification was 0.764 ng/mL.
Statistical analysis
The primary analyses for the efficacy endpoints were per-
formed for the full analysis set (FAS) and per-protocol set
(PPS). The FAS was defined as all enrolled patients who
received ≥1 dose of study drug. Patients who did not de-
velop symptomatic DVT or PE, and in whom venography
was not appropriately performed, were excluded from the
FAS. The PPS included patients in the FAS but excluded
those with violations to the inclusion/exclusion criteria,
those who received prohibited concomitant medications
or therapies, or whose study treatment compliance rate
was <80 %. Safety analyses were performed for the safety
analysis set (SAS), defined as all patients who received ≥1
dose of study drug. The pharmacokinetic (PK) analysis set
included patients in the PPS with valid plasma drug con-
centration measured at ≥1 time points.
For all comparisons of the primary, secondary, and
safety endpoints, a paired comparison was performed be-
tween treatment groups using the χ2 test, with a two-sided
significance level of 0.05 and a two-sided confidence coef-
ficient of 0.95. In the primary efficacy analysis, the inci-
dence of the primary endpoint and 95 % confidence
intervals (CIs) were calculated for each treatment group.
The difference in the incidence of the primary endpoint
between edoxaban and enoxaparin and its corresponding
95 % CI were then calculated using the Farrington-
Manning method to test for noninferiority [13]. The non-
inferiority margin was set at 8 % for the difference in the
primary endpoint between the two groups, with a 1-sided
significance level of 0.025. This noninferiority margin was
chosen as it was less than half of the reduction in VTE in-
cidence, estimated to be at least approximately 18 % based
on the incidence of VTE in Japanese patients undergoing
THA (27.3 %; 95 % CI 22.2, 32.9) given in the “Japanese
Guideline for the Prevention of Venous Thromboem-
bolism” [14] and the incidence of VTE with twice-daily
enoxaparin 20 mg used in the phase 2b study of patients
undergoing THA (4.1 %) [15]. If noninferiority was estab-
lished, edoxaban would be considered superior to enoxa-
parin if the upper limit of the 95 % CI calculated for the
difference in the primary endpoint between the two
groups was below 0 %. Similar analyses were performed
for the secondary efficacy endpoints.
The incidence of major bleeding events and correspond-
ing 95 % CIs during the treatment period were calculated
for each treatment group. The difference in the incidences
of major bleeding between the edoxaban and enoxaparin
groups and its 95 % CI were also calculated. Similar
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CRNM bleeding, minor bleeding, and any bleeding events.
The overall incidences of AEs and ADRs and their
95 % CIs were calculated by treatment group. Hepatic
dysfunction was classified by the extent of the increase
of liver function parameters above the ULN, and the
frequency of abnormal changes was summarized.
The number of patients necessary to verify noninferior-
ity was calculated to be 235 patients per treatment group,
providing ≥90 % power assuming a VTE incidence of 6 %.
Assuming that the proportion of patients excluded from
analyses would be approximately 20 %, the planned num-
ber of patients was set at 600 (300/group).
Results
Patient disposition
Between May 2009 and January 2010, 610 patients were
randomized: 307 patients to edoxaban and 303 to enoxa-
parin (Fig. 2). Of the randomized patients, 604 received ≥1
dose of medication and were included in the SAS. Venog-
raphy was unassessable in 101 patients (48 and 53 in the
edoxaban and enoxaparin groups, respectively), resulting
in 503 patients included in the FAS. During the study
period, 23 patients in the edoxaban group and 32 patients
in the enoxaparin group discontinued treatment. In both
groups, the most common reasons for discontinuation
were AEs and voluntary patient withdrawal. In theFig. 2 Patient disposition. IU, international unitedoxaban group, nine patients withdrew due to AEs, six
patients voluntarily withdrew, three patients were found
to be ineligible, and the investigator judged withdrawal
was appropriate for two patients. In the enoxaparin group,
ten patients withdrew due to AEs, eight patients voluntar-
ily withdrew, and the investigator judged withdrawal was
appropriate for three patients. There were no clinically
relevant differences in baseline characteristics between the
treatment groups (Table 1). Mean age was 62.8 years and
mean body weight was 57.4 kg. Overall, most patients
were female (86 %), <75 years of age (87 %), weighed
<60 kg (63 %), and had a CLCR of ≥80 mL/min (59 %).
Mean treatment duration for both groups was 12.5 days.
Physiotherapy was used in at least 80 % of patients and
was balanced between groups.
Outcome measures
The incidence of VTE is shown in Table 2. All thrombo-
embolic events were asymptomatic DVT, as neither symp-
tomatic DVT nor PE developed in either treatment group.
In the FAS, the primary efficacy outcome occurred in 2.4 %
(6/255) of patients receiving edoxaban and in 6.9 % (17/
248) receiving enoxaparin, resulting in a relative risk reduc-
tion of 65.7 % (P <0.001). The absolute difference for the
primary efficacy endpoint was −4.5 % (95 % CI: −8.6, −0.9)
and was within the noninferiority margin, thereby establish-
ing that edoxaban was noninferior to enoxaparin for the
Table 1 Baseline characteristics
Characteristic Edoxaban 30 mg
QD (n = 255)
Enoxaparin 2000 IU
BID (n = 248)
Sex
Female 220 (86.3) 212 (85.5)
Age (y)
Mean ± SD 62.8 ± 9.61 62.8 ± 9.72
<75 220 (86.3) 217 (87.5)
≥75 35 (13.7) 31 (12.5)
Weight (kg)
Mean ± SD 57.7 ± 9.72 57.0 ± 9.60
<60 160 (62.7) 157 (63.3)
≥60 95 (37.3) 91 (36.7)
BMI, mean ± SD 24.5 ± 3.52 24.2 ± 3.60
CLCR (mL/min)
Mean ± SD 89.6 ± 29.58 88.9 ± 26.49
≥80 148 (58.0) 150 (6)
≥50 to <80 93 (36.5) 91 (36.7)
<50 14 (5.5) 7 (2.8)
History of artificial joint
replacement of the
lower limbs
39 (15.3) 35 (14.1)
Duration from the end
of surgery to the start
of study treatment (h)
≥12 to <18 16 (6.3) -
≥18 to ≤24 239 (93.7) -
≥24 to <30 - 170 (68.5)
≥30 to <36 - 78 (31.5)





137 (53.7) 135 (54.4)
Intermittent pneumatic
compression therapy
(lower legs and thigh)
120 (47.1) 114 (46.0)
Elastic stockings 209 (82.0) 201 (81.0)
Concomitant NSAIDs 250 (98.0) 243 (98.0)
Treatment duration (days)
Mean ± SD 12.5 (1.4) 12.5 (1.5)
Data presented as n (%) unless otherwise stated. BID, twice daily; BMI,
body mass index; CLCR, creatinine clearance; IU, international unit; NSAIDs,
non-steroidal anti-inflammatory drugs; QD, once daily; SD, standard deviation
aPatients could be using more than one mode of physiotherapy
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the absolute difference was less than 0 %, the superiority of
edoxaban over enoxaparin was demonstrated.
Among patients who utilized physiotherapy, there was a
significant reduction in the incidence of VTE with use of
elastic stockings in the edoxaban group compared withthe enoxaparin group (1.9 % [4/209] vs 7.5 % [15/201], re-
spectively; P = 0.004). The incidences of VTE as assessed
by venography were similar between the edoxaban and
enoxaparin groups with intermittent pneumatic compres-
sion therapy of the sole of the foot (2.9 % [4/137] vs 4.4 %
[6/135], respectively) and of the lower legs and thigh
(4.2 % [5/120] vs 5.3 % [6/114], respectively).
The incidence of symptomatic DVT, proximal DVT,
symptomatic PE, or VTE-related death was 0.4 % (1/255)
in the edoxaban group and 0.8 % (2/248) in the enoxaparin
group (Table 2). All events were asymptomatic, proximal
DVT. The absolute difference in the incidence was −0.4 %
(95 % CI: −2.5, 1.5), with no clear differences between the
two groups (Table 2). No VTE-related deaths occurred
during the study. Primary and secondary efficacy outcomes
for the PPS population paralleled those of the FAS.Safety
The incidence of major bleeding was 0.7 % and 2.0 % in
the edoxaban and enoxaparin groups, respectively, for an
absolute difference of −1.3 % (P = 0.176) (Table 3). Clinic-
ally relevant nonmajor bleeding was reported by 2.0 % and
1.7 % of patients in the edoxaban and enoxaparin groups,
respectively (P = 0.769). There was no significant difference
in the incidence of major or CRNM bleeding during the
treatment period in the edoxaban group (2.6 %) compared
with the enoxaparin group (3.7 %; P = 0.475). Breakdowns
of major and CRNM bleeding events are provided in
Table 3. The incidence of any bleeding events (major,
CRNM, and minor bleeding) was 20.5 % vs 15.9 % in the
edoxaban and enoxaparin groups, respectively (P = 0.151).
The incidence of minor bleeding events was significantly
greater in the edoxaban group compared with the enoxa-
parin group (P = 0.049). The presence of blood in the urine
was characterized as minor bleeding, and occurred in 38
patients in the edoxaban group (12.5 %) and 34 patients in
the enoxaparin group (11.3 %). No cases of fatal bleeding
occurred in either group.
The overall incidence of AEs from the start of treatment
to the day of the follow-up examination was 65.0 % (197/
303) in the edoxaban group and 77.1 % (232/301) in the
enoxaparin group (Table 4). The most common AEs that
occurred in ≥5 % of either treatment groups were in-
creased γ-glutamyltransferase, blood present in the urine,
increased ALT, increased AST, increased blood alkaline
phosphatase, and subcutaneous hemorrhage. Elevated
ALT or AST levels ≥3 times the ULN was higher in the
enoxaparin group (10.0 %) than in the edoxaban group
(2.6 %; Table 4). The pattern of the incidence of ADRs was
similar to that of AEs. All AEs and ADRs were mild or
moderate in intensity. The incidences of AEs and ADRs
excluding bleeding events and hepatic dysfunction were
41.6 % and 11.2 %, respectively, in the edoxaban group,
Table 2 Incidence of thromboembolic events
Outcome Edoxaban 30 mg QD (n = 255) Enoxaparin 2000 IU BID (n = 248) Absolute difference %
(95 % CI)n (%) 95 % CI n (%) 95 % CI
Primary efficacy (any VTE) 6 (2.4) 1.1, 5.0 17 (6.9) 4.3, 10.7 −4.5 (−8.6, −0.9)a,b
Asymptomatic DVT
Totalc 6 (2.4) 1.1, 5.0 17 (6.9) 4.3, 10.7 −4.5 (−8.6, −0.9)
Proximal 1 (0.4) 0.1, 2.2 2 (0.8) 0.2, 2.9 −0.4 (−2.5, 1.5)
Distal 6 (2.4) 1.1, 5.0 16 (6.5) 4.0, 10.2 −4.1 (−8.1, −0.6)
Symptomatic DVT 0 (0.0) 0.0, 1.5 0 (0.0) 0.0, 1.5 0.0
Symptomatic PE 0 (0.0) 0.0, 1.5 0 (0.0) 0.0, 1.5 0.0
VTE-related death 0 (0.0) 0.0, 1.5 0 (0.0) 0.0, 1.5 0.0
Symptomatic DVT, proximal DVT,
symptomatic PE, or VTE-related death
1 (0.4) 0.1, 2.2 2 (0.8) 0.2, 2.9 −0.4 (−2.5, 1.5)
BID, twice daily; CI, confidence interval; DVT, deep vein thrombosis; IU, international unit; PE, pulmonary embolism; QD, once daily; VTE, venous thromboembolism
ap <0.001 as calculated by the noninferiority Farrington-Manning test; bp = 0.0157 as calculated by the superiority Farrington-Manning test; cone patient had both
a proximal and a distal DVT
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group.
There was no difference in the incidence of serious
AEs (SAEs) between the edoxaban (3.0 %) and enoxa-
parin (3.0 %) treatment groups. Nine SAEs occurred in
the edoxaban group; for all of these, a causal relationship
was ruled out by the investigator. In the enoxaparin
group, 10 SAEs occurred; for nine of them, a causal rela-
tionship was ruled out, excluding one case of postopera-
tive wound infection.Table 3 Incidence of bleeding events during the treatment period
Event Edoxaban 30 mg QD (n = 303)
n (%) 95 % CI
Major bleeding 2 (0.7) 0.2, 2.4
Subcutaneous hemorrhage 1 (0.3) NC
Wound hemorrhage 1 (0.3) -
Duodenal ulcer hemorrhage 0 (0.0) -
Hemarthrosis 0 (0.0) -
CRNM bleeding 6 (2.0) 0.9, 4.3
Subcutaneous hemorrhage 1 (0.3) NC
Wound hemorrhage 1 (0.3) -
Conjunctival hemorrhage 1 (0.3) -
Epistaxis 1 (0.3) -
Lower gastrointestinal hemorrhage 1 (0.3) -
Hematuria 1 (0.3) -
Postprocedural hematoma 0 (0.0) -
Subcutaneous hematoma 0 (0.0) -
Major or CRNM bleeding 8 (2.6) 1.3, 5.1
Minor bleeding 57 (18.8) 14.8, 23.6
Any bleeding 62 (20.5) 16.3, 25.4
BID, twice daily; CI, confidence interval; CRNM, clinically relevant nonmajor bleeding
Patients could have multiple bleeds, which were counted individuallyPlasma concentrations of edoxaban
The PK analysis set included a cohort of 250 patients.
However, laboratory anomalies detected after remediation
of the bioanalytic results identified 36 samples as inevalu-
able, leaving 214 patients in the updated PK analysis set.
The mean (standard deviation) edoxaban plasma concen-
tration in these 214 patients at predose on day seven of
treatment was 17.8 (12.1) ng/mL. The plasma concentra-
tion was similar to the results obtained in the original PK
analysis set of 250 patients before remediation.Enoxaparin 2000 IU BID (n = 301) Absolute difference %
(95 % CI)
P
n (%) 95 % CI
6 (2.0) 0.9, 4.3 −1.3 (−3.7, 0.7) 0.176
2 (0.7) NC NC NC
1 (0.3) - - -
2 (0.7) - - -
1 (0.3) - - -
5 (1.7) 0.7, 3.8 0.3 (−2.1, 2.8) 0.769
0 (0.0) NC NC NC
0 (0.0) - - -
0 (0.0) - - -
0 (0.0) - - -
0 (0.0) - - -
1 (0.3) - - -
3 (1.0) - - -
1 (0.3) - - -
11 (3.7) 2.1, 6.4 −1.0 (−4.1, 1.9) 0.475
39 (13.0) 9.6, 17.2 5.9 (0.0, 11.7) 0.049
48 (15.9) 12.2, 20.5 4.5 (−1.7, 10.7) 0.151
; IU, international unit; NC, not calculated; QD, once daily
Table 4 Adverse events, adverse drug reactions, and abnormal
changes in hepatic function
Edoxaban 30 mg
QD (n = 303)
Enoxaparin 2000 IU
BID (n = 301)
Adverse events
Patients with events 197 (65.0) 232 (77.1)
95 % CI 59.5, 70.2 72.0, 81.5
Number of events 448 676
Adverse events reported
by ≥5 % of patients in
either treatment groupa
ALT increased 36 (11.9) 126 (41.9)
AST increased 17 (5.6) 97 (32.2)
γ-glutamyltransferase
increased
44 (14.5) 79 (26.2)
Blood urine present 38 (12.5) 34 (11.3)
Blood alkaline phosphatase
increased
14 (4.6) 40 (13.3)
Hemorrhage subcutaneous 12 (4.0) 21 (7.0)
Adverse drug reactions
Patients with events 121 (39.9) 177 (58.8)
95 % CI 34.6, 45.5 53.2, 64.2




≥1.5 x ULN 43 (14.2) 135 (44.9)
≥3 x ULN 8 (2.6) 30 (10.0)
≥5 x ULN 2 (0.7) 11 (3.7)
Data are presented as n (%) unless otherwise indicated. ALT, alanine
aminotransferase; AST, aspartate aminotransferase; BID, twice daily; CI,
confidence interval; IU, international unit; QD, once daily; ULN, upper limit
of normal
aClassified by MedDRA/J V.12.0 Preferred Term
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The STARS J-V trial demonstrated the noninferiority and
superiority of once-daily oral edoxaban 30 mg to twice-
daily subcutaneous enoxaparin 2000 IU for the prevention
of VTE in Japanese patients undergoing elective unilateral
THA based on venography. Although no symptomatic PE
occurred, this was not unexpected, as the rate of symp-
tomatic PE following THA or TKA has a very low event
rate of 0.55 % in Japan [16]. The incidence of VTE for pa-
tients receiving edoxaban 30 mg has been previously ex-
plored in phase 2b studies of patients undergoing TKA or
THA [9, 11]. In a study evaluating edoxaban vs enoxa-
parin in patients undergoing THA in Japan and Taiwan
[11], the incidence of thromboembolic events in the edox-
aban 30-mg group (2.8 %) was consistent with the current
study (2.4 %). In a placebo-controlled study in Japanese
patients undergoing TKA [9], VTE occurred in 12.5 % of
patients in the edoxaban 30-mg once-daily treatmentgroup, which is higher than the incidence of VTE reported
in the edoxaban group in this study. The higher rate of
VTE may be explained by an older population in the
phase 2b TKA study compared with STARS J-V (mean
age 71.4 vs 62.8 years). A recent analysis by Rohatagi, et al.
[17] explored the exposure vs response relationship be-
tween edoxaban and VTE rates using pharmacometric
analyses. In addition to a direct relationship between
edoxaban exposure and the incidence of VTE, they
showed that increasing age is a risk factor for VTE [17].
In this study, the incidences of any bleeding and major
or CRNM bleeding events were similar for edoxaban and
enoxaparin. In addition, the rates of major or CRNM
bleeding events in patients receiving edoxaban 30 mg
were low in our study (2.6 %) and similar to the phase 2b
studies in TKA and THA (3.9 % and 1.2 %, respectively)
[9, 11]. The incidence of any bleeding was higher in our
study (20.5 %) compared with that observed in the edoxa-
ban 30-mg treatment group in the phase 2 TKA trial
(10.7 %) [9]. Although the rates of major bleeding and
CRNM bleeding were low and similar between these
studies, the incidence of minor bleeding was high for
edoxaban in our study (18.8 %). Reasons for the higher
rate of minor bleeding in the edoxaban group are not
clear. Higher rates of bleeding may be attributed, at
least in part, to the very high rate of NSAID use—98 %
of patients in the edoxaban group concomitantly used
NSAIDs compared to 81 % in the enoxaparin group. In
a retrospective analysis of pooled data from four phase
3 studies evaluating the safety and efficacy of rivaroxa-
ban compared with enoxaparin for the prevention of
VTE after THA or TKA, the risk of bleeding increased
with concomitant use of NSAIDs in either treatment
group [18]. Higher rates of major bleeding following
administration of low molecular weight heparin have
been reported at 2–4 h postoperatively compared with
12–48 h postoperatively, suggesting that higher levels
of anticoagulation earlier may be associated with more
bleeding events [19]. As edoxaban was initiated with an
earlier start than enoxaparin, this may contribute to the
higher observed rates of minor bleeding. Lastly, no fatal
bleeding or bleeding of critical sites (eg, intracranial
bleeding) occurred in this study.
The incidence of all AEs in this study was lower in
the edoxaban group than in the enoxaparin group. In
addition, elevations in ALT or AST were seen in fewer
patients in the edoxaban group vs the enoxaparin
group. However, it should be noted that elevated serum
transaminase levels are recognized as a class effect of
heparins. These elevations are transient and reversible
and considered benign [20]. Overall bleeding events
were more common with edoxaban. The AEs other
than bleeding events and AEs related to abnormal
hepatic function test values were similar between both
Fuji et al. Thrombosis Journal  (2015) 13:27 Page 8 of 9treatment groups. In addition, the incidence of SAEs was
similar in both the edoxaban and enoxaparin groups.
Other oral direct factor inhibitors have been compared
with subcutaneous enoxaparin 40 mg for thrombopro-
phylaxis following elective hip replacement and have
also been shown to effectively reduce the risk for VTE
postsurgery without increasing the risk for clinically
relevant bleeding [21–23]. However, in these studies,
only 0 %–6.8 % of randomized patients were Asian. It
should be noted that in the current study, the Japanese
patient population was smaller than the population in
the other THA studies, which had enrolled patients
from Western countries. Additionally, the dose of enoxa-
parin used (2000 IU, twice daily) is a recommendation
specific to Japan for the prevention of VTE [4]. Japanese
patients typically have a lower body weight than patients
from the United States or the European Union; notably
the mean body weight in this study was 57 kg compared
with a mean body weight of 78 kg for patients in the
phase 3 trial for rivaroxaban in THA, which included
primarily white patients (92 %) [21]. A body weight for
males >57 kg is associated with increased enoxaparin
exposure and increased bleeding risk for prophylactic,
subcutaneous enoxaparin doses of 40 mg once daily or
30 mg twice daily [24]. Thus, these results are primarily
relevant to Japanese patients.
In conclusion, the STARS J-V study demonstrated the
superiority of oral once-daily edoxaban 30 mg compared
with twice-daily subcutaneous injection of enoxaparin
2000 IU for the prevention of VTE in Japanese patients
after THA, without an increased risk of bleeding or AEs.
The favorable efficacy-to-safety balance of edoxaban
suggests an attractive option for thromboprophylaxis in
patients following THA.
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